Table 9 Medical characteristics for participating patients at T1 (N = 42)
Dublin centre (n = 19) | Non-Dublin centre (n = 23) | |||
|---|---|---|---|---|
Men (n = 18) | Women (n = 1) | Men (n = 18) | Women (n = 5) | |
Cardiac procedures | ||||
Stenting (angioplasty or PTCA) | 13 (72.2%) | 1 (100%) | 16 (88.9%) | 3 (60%) |
Bypass graft (coronary artery bypass graft) | 3 (16.7%) | 0 (0%) | 3 (16.7%) | 0 (0%) |
Cardiac and other medical conditions | ||||
Acute coronary syndrome | 0 (0%) | 0 (0%) | 1 (5.6%) | 0 (0%) |
Angina | 2 (11.1%) | 1 (100%) | 3 (16.7%) | 1 (20%) |
Anxiety | 1 (5.6%) | 0 (0%) | 0 (0%) | 1 (20%) |
COPD | 0 (0%) | 0 (0%) | 2 (11.1%) | 1 (20%) |
Coronary heart disease | 5 (27.8%) | 1 (100%) | 8 (44.4%) | 2 (40%) |
Depression | 2 (11.1%) | 0 (0%) | 1 (5.6%) | 1 (20%) |
Diabetes | 2 (11.1%) | 0 (0%) | 0 (0%) | 0 (0%) |
Heart attack | 4 (22.2%) | 0 (0%) | 9 (50%) | 4 (80%) |
High blood pressure | 8 (44.4%) | 1 (100%) | 7 (38.9%) | 3 (60%) |
High cholesterol | 12 (66.7%) | 0 (0%) | 8 (44.4%) | 1 (20%) |
Prostate cancer | 0 (0%) | n/a | 0 (0%) | n/a |
Stroke | 1 (5.6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Use of sexual performance medications | 1 (5.6%) | 0 (0%) | 3 (16.7%) | 0 (0%) |
Cardiovascular medications | ||||
Anti-coagulants/blood thinners | 7 (38.9%) | 1 (100%) | 9 (50%) | 2 (40%) |
Antiplatelet agents | 15 (83.3%) | 0 (0%) | 17 (94.4%) | 5 (100%) |
ACE inhibitors | 3 (16.7%) | 0 (0%) | 5 (27.8%) | 3 (60%) |
Angiotension II receptor blockers | 3 (16.7%) | 1 (100%) | 2 (11.1%) | 0 (0%) |
Beta blockers | 14 (77.8%) | 1 (100%) | 13 (72.2%) | 3 (60%) |
Calcium channel blockers | 1 (5.6%) | 0 (0%) | 1 (5.6%) | 0 (0%) |
Cholesterol-lowering medications/statins | 15 (83.3%) | 1 (100%) | 17 (94.4%) | 3 (60%) |
Digitalis preparations | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Diuretics | 1 (5.6%) | 0 (0%) | 2 (11.1%) | 2 (40%) |
Other | 4 (22.2%) | 1 (100%) | 9 (50%) | 0 (0%) |